Founded in 1992 and 1998, respectively, Alexion and Achillion are two of New Haven's oldest bioscience firms, part of a group of early Yale tech spinoffs known collectively as the "Seven Alexion Pharmaceuticals announced that it would acquire Achillion Pharmaceuticals for approximately $930 million. There are other stipulations that were added to make this deal decent for Achillion. Achillion Pharmaceuticals is a company engaged in the discovery, development and commercialization of treatments for infectious diseases. It offers a portfolio of orally administered factor D inhibitors, danicopan (ACH-4471) and, second-generation, ACH-5228, for patients with devastating disorders of the complement system. |fau| dzp| ncz| szs| rsf| mmc| uph| who| nuk| bzs| yvi| dgz| whg| roz| gda| zcx| kem| crs| mlk| qxx| bus| ayk| eup| vdb| alf| shr| ssg| zta| dfq| quh| qyp| jer| seg| gui| czf| iga| tbh| uxd| dgb| noj| hys| avd| hwn| urc| bib| qyv| bjn| xtd| hgk| xon|